Stock Traders Purchase Large Volume of Call Options on Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was the recipient of some unusual options trading activity on Monday. Stock traders purchased 11,259 call options on the company. This represents an increase of 2,053% compared to the average daily volume of 523 call options.

Institutional Trading of Sangamo Therapeutics

Several institutional investors have recently added to or reduced their stakes in SGMO. Wasatch Advisors LP raised its holdings in Sangamo Therapeutics by 62.4% in the first quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock valued at $13,493,000 after acquiring an additional 7,734,400 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Sangamo Therapeutics by 14.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock worth $561,000 after purchasing an additional 129,811 shares during the period. Acadian Asset Management LLC raised its holdings in shares of Sangamo Therapeutics by 3.7% during the third quarter. Acadian Asset Management LLC now owns 2,927,769 shares of the biopharmaceutical company’s stock worth $1,753,000 after purchasing an additional 105,789 shares during the period. SG Americas Securities LLC raised its holdings in shares of Sangamo Therapeutics by 103.9% during the fourth quarter. SG Americas Securities LLC now owns 180,544 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 92,002 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Sangamo Therapeutics by 10.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 676,189 shares of the biopharmaceutical company’s stock worth $406,000 after purchasing an additional 62,465 shares during the period. 56.93% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on SGMO shares. StockNews.com initiated coverage on shares of Sangamo Therapeutics in a report on Tuesday, February 13th. They issued a “sell” rating for the company. Royal Bank of Canada reiterated a “sector perform” rating and set a $2.00 price objective on shares of Sangamo Therapeutics in a research note on Thursday, March 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $5.00 price objective (up from $3.00) on shares of Sangamo Therapeutics in a research note on Tuesday, March 19th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $4.93.

Sangamo Therapeutics Trading Up 2.1 %

NASDAQ SGMO opened at $0.52 on Wednesday. The company’s fifty day simple moving average is $0.81 and its 200-day simple moving average is $0.59. Sangamo Therapeutics has a 52 week low of $0.29 and a 52 week high of $1.78. The stock has a market cap of $93.19 million, a P/E ratio of -0.35 and a beta of 1.39.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.09). Sangamo Therapeutics had a negative return on equity of 82.17% and a negative net margin of 146.30%. The firm had revenue of $2.04 million for the quarter, compared to analyst estimates of $8.96 million. On average, research analysts expect that Sangamo Therapeutics will post -0.54 EPS for the current fiscal year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.